Biomarin Pharmaceutical Inc (NAS:BMRN)
$ 67.2898 0.2198 (0.33%) Market Cap: 12.82 Bil Enterprise Value: 12.46 Bil PE Ratio: 40.29 PB Ratio: 2.37 GF Score: 69/100

Biomarin Pharmaceutical Inc at Jefferies Gene Therapy Summit Transcript

Oct 08, 2019 / 03:15PM GMT
Release Date Price: $64.83 (-1.53%)
Eun Kyung Yang
Jefferies LLC, Research Division - MD & Senior Equity Research Analyst

Okay. Continuing the theme of manufacturing of gene therapy. So I'm happy to have Dr. Robert Baffi, who is the President of Global Manufacturing and Technical Operations at BioMarin. So today's fireside chat is going to be more focused on gene therapy manufacturing. So let's start with AAV manufacturing platforms and there are few of them. So you briefly talked about baculovirus insect cell system, the advantage of gene cell panel. But can you -- because the panel discussion was now what guessed it.

Questions & Answers

Eun Kyung Yang
Jefferies LLC, Research Division - MD & Senior Equity Research Analyst

So can you give us a brief summary of why -- what's the decision that you made to chose to go with baculovirus insect system?

Robert A. Baffi
BioMarin Pharmaceutical Inc. - President of Global Manufacturing & Technical Operations

Yes. So when we first in-licensed the program from University College London

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot